Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy

US9605320B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Arash Ash Alizadeh · San Mateo, US
• Dan Denney · Fremont, US
• Ronald Levy · Palo Alto, US

Key dates

• Filing date: Jan 10, 2012
• Grant date: Mar 28, 2017
• Expiry date: Sep 27, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig+) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Yhi) is predictive of a low anti tumor response.